Inactive Instrument

Highlights Bioblast Pharma Ltd Nasdaq

Equities

IL0011319527

Highlights

Unlock all the news: Be the first to know and act before the market!

Enlivex Therapeutics Ltd. Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis	24/06	CI
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis	17/06	CI
Enlivex Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/06	CI
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis	03/06	CI
Enlivex Therapeutics to Launch Registered Direct Offering; Shares Fall	29/05	MT
Enlivex Therapeutics Ltd. Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra? in Patients with Knee Osteoarthritis	22/04	CI
Enlivex Therapeutics Receives Approval to Expand Trial of Allocetra to Treat Knee Osteoarthritis Into Denmark	16/04	MT
Enlivex Therapeutics Ltd Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis	16/04	CI
Sector Update: Health Care Stocks Softer Late Afternoon	12/04	MT
Sector Update: Health Care	12/04	MT
Enlivex Therapeutics Shares Fall After Topline Data from Sepsis Treatment Study	11/04	MT
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra? in Patients with Sepsis	11/04	CI
Tranche Update on Enlivex Therapeutics Ltd.'s Equity Buyback Plan announced on September 18, 2023.	30/03	CI
Enlivex Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	30/03	CI
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method	07/02	CI
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis	17/01	CI
Enlivex Therapeutics Ltd.'s Equity Buyback Plan Extended till June 30, 2024.	17/01	CI
Enlivex Therapeutics Ltd. Announces Completion of Enrollment of its Phase II Trial Evaluating Allocetra in Patients with Sepsis	20/12	CI
Enlivex Therapeutics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Enlivex Therapeutics Ltd. announces an Equity Buyback for $1.5 million worth of its shares.	18/23/18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Bioblast Pharma Ltd Nasdaq

Equities

IL0011319527

Highlights

Filters